Long-term safety and efficacy of long-acting pasireotide in acromegaly

被引：0
作者：
Amit Akirov
Alexander Gorshtein
Idit Dotan
Nariman Saba Khazen
Yulia Pauker
Michal Gershinsky
Ilan Shimon
机构：
[1] Beilinson Hospital,Institute of Endocrinology
[2] Tel-Aviv University,Sackler School of Medicine
[3] Clalit Medical Services,Linn Medical Center
来源：
Endocrine | 2021年 / 74卷
关键词：
Acromegaly; Growth hormone; Hyperglycemia; Pasireotide LAR;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：396 / 403
页数：7
相关论文
共 50 条
  • [31] Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing's disease: interim results from a long-term real-world evidence study
    Manetti, Luca
    Deutschbein, Timo
    Schopohl, Jochen
    Yuen, Kevin C. J.
    Roughton, Michael
    Kriemler-Krahn, Ulrike
    Tauchmanova, Libuse
    Maamari, Ricardo
    Giordano, Carla
    PITUITARY, 2019, 22 (05) : 542 - 551
  • [32] Intraoperative Prediction of Long-Term Remission in Acromegaly
    Zachariah, Marcus A.
    Bozer, Jordan J.
    Cua, Santino
    Prevedello, Luciano M.
    Ghalib, Luma M.
    Hardesty, Douglas A.
    Carrau, Ricardo L.
    Kirschner, Lawrence S.
    Prevedello, Daniel M.
    OPERATIVE NEUROSURGERY, 2023, 24 (01) : 74 - 79
  • [33] Safety of long-term use of daily and long-acting growth hormone in growth hormone-deficient adults on cancer risk
    Boguszewski, Cesar Luiz
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 37 (06)
  • [34] Pharmacokinetics and pharmacodynamics of a pasireotide subcutaneous depot (CAM4071) and comparison with immediate and long-acting release pasireotide
    Johnsson, Markus
    Pedroncelli, Alberto M.
    Hansson, Anna
    Tiberg, Fredrik
    ENDOCRINE, 2024, 84 (03) : 1125 - 1134
  • [35] Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naive to radiation and medical therapy
    Ghigo, E.
    Biller, B. M. K.
    Colao, A.
    Kourides, I. A.
    Rajicic, N.
    Hutson, R. K.
    De Marinis, L.
    Klibanski, A.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2009, 32 (11) : 924 - 933
  • [36] Double benefit of long-acting somatostatin analogs in a patient with coexistence of acromegaly and ulcerative colitis
    Yarman, S.
    Yalin, G. Y.
    Dogansen, S. C.
    Canbaz, B.
    Tanrikulu, S.
    Akyuz, F.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2016, 41 (05) : 559 - 562
  • [37] Efficacy and safety of fractionated conformal radiation therapy in acromegaly: a long-term follow-up study
    Gonzales-Virla, Baldomero
    Vargas-Ortega, Guadalupe
    Martinez-Vazquez, Karen-Belen
    Espinosa de lo Monteros, Ana Laura
    Sosa-Erosa, Ernesto
    Lopez-Felix, Blas
    Mendoza-Zubieta, Victoria
    Mercado, Moises
    ENDOCRINE, 2019, 65 (02) : 386 - 392
  • [38] Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly
    Kendall-Taylor P.
    Miller M.
    Gebbie J.
    Turner S.
    Al-Maskari M.
    Pituitary, 2000, 3 (2) : 61 - 65
  • [39] Efficacy and adverse events of octreotide long-acting release in acromegaly: a real-world retrospective study
    Zhao, Zhe
    Duan, Lian
    Gao, Daihui
    Yao, Yong
    Deng, Kan
    Xing, Bing
    Wang, Xinfeng
    Tang, Yan
    Zhu, Huijuan
    Chen, Xiaoguang
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (13)
  • [40] TREATMENT OF ACROMEGALY WITH A LONG-ACTING FORMULATION OF LANREOTIDE - A NEW SOMATOSTATIN ANALOG
    HERON, I
    THOMAS, F
    DERO, M
    POUTRAIN, JR
    HENANE, S
    CATUS, F
    KUHN, JM
    PRESSE MEDICALE, 1993, 22 (11): : 526 - 531
12345